Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors
Open Access
- 1 January 2021
- journal article
- research article
- Published by Wiley in Clinical & Translational Immunology
- Vol. 10 (5), e1285
- https://doi.org/10.1002/cti2.1285
Abstract
Objectives Characterisation of the human antibody response to SARS-CoV-2 infection is vital for serosurveillance purposes and for treatment options such as transfusion with convalescent plasma or immunoglobulin products derived from convalescent plasma. In this study, we longitudinally and quantitatively analysed antibody responses in RT-PCR-positive SARS-CoV-2 convalescent adults during the first 250 days after onset of symptoms. Methods We measured antibody responses to the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein and the nucleocapsid protein in 844 longitudinal samples from 151 RT-PCR-positive SARS-CoV-2 convalescent adults. With a median of 5 (range 2–18) samples per individual, this allowed quantitative analysis of individual longitudinal antibody profiles. Kinetic profiles were analysed by mixed-effects modelling. Results All donors were seropositive at the first sampling moment, and only one donor seroreverted during follow-up analysis. Anti-RBD IgG and anti-nucleocapsid IgG levels declined with median half-lives of 62 and 59 days, respectively, 2–5 months after symptom onset, and several-fold variation in half-lives of individuals was observed. The rate of decline of antibody levels diminished during extended follow-up, which points towards long-term immunological memory. The magnitude of the anti-RBD IgG response correlated well with neutralisation capacity measured in a classic plaque reduction assay and in an in-house developed competitive assay. Conclusion The result of this study gives valuable insight into the long-term longitudinal response of antibodies to SARS-CoV-2.Keywords
Funding Information
- ZonMw (10430 01 201 0012)
- European Commission (101015756)
This publication has 38 references indexed in Scilit:
- Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccineCellular & Molecular Immunology, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Identification of a novel coronavirus causing severe pneumonia in human: a descriptive studyChinese Medical Journal, 2020
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor bindingThe Lancet, 2020
- Evaluation of MERS-CoV Neutralizing Antibodies in Sera Using Live Virus Microneutralization AssayPublished by Springer Science and Business Media LLC ,2019
- The Maintenance of Memory Plasma CellsFrontiers in Immunology, 2019
- Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector ActivitiesFrontiers in Immunology, 2017
- Living on Three Time Scales: The Dynamics of Plasma Cell and Antibody Populations Illustrated for Hepatitis A VirusPLoS Computational Biology, 2012
- Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potentialNature Communications, 2011
- Disappearance of Antibodies to SARS-Associated Coronavirus after RecoveryThe New England Journal of Medicine, 2007